| CAS NO: | 210344-98-2 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 2mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Molecular Weight (MW) | 654.68 |
|---|---|
| Formula | C30H43FN4O11 |
| CAS No. | 210344-98-2 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 91 mg/mL (138.99 mM) |
| Water:<1 mg/mL (slightly soluble or insoluble) | |
| Ethanol: <1 mg/mL | |
| Other info | Synonym: Z-IE(OMe)TD(OMe)-FMK; Granzyme B Inhibitor III; Z-IETD-FMK; Z-Ile-Glu(OMe)-Thr-Asp(OMe)-CH2F. Chemical Name: (5S,8S,11S,14S)-5-((S)-sec-butyl)-8-(2-carboxyethyl)-14-(2-fluoroacetyl)-11-((R)-1-hydroxyethyl)-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,13-tetraazahexadecan-16-oic acid InChi Key: CTXDBLYOEUERAT-VUVYEONESA-N InChi Code: InChI=1S/C28H39FN4O11/c1-4-15(2)23(33-28(43)44-14-17-8-6-5-7-9-17)26(41)30-18(10-11-21(36)37)25(40)32-24(16(3)34)27(42)31-19(12-22(38)39)20(35)13-29/h5-9,15-16,18-19,23-24,34H,4,10-14H2,1-3H3,(H,30,41)(H,31,42)(H,32,40)(H,33,43)(H,36,37)(H,38,39)/t15-,16+,18-,19-,23-,24-/m0/s1 SMILES Code: O=C(O)C[C@@H](C(CF)=O)NC([C@H]([C@H](O)C)NC([C@H](CCC(O)=O)NC([C@H]([C@@H](C)CC)NC(OCC1=CC=CC=C1)=O)=O)=O)=O |
| Chemical Name | L-Threoninamide, N-[(phenylmethoxy)carbonyl]-L-isoleucyl-L-α-glutamyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-, methyl ester |
| In Vitro | Z-IETD-FMK, which inhibits the cleavage of caspase-8 and partially inhibits the cleavage of caspase-3 and PARP, prevents the execution of apoptosis in retinal cells exposed to different apoptotic stimuli. Z-IETD-FMK (50 μM) reduces ceramide-induced cardiomyocyte death and significantly inhibits the activation of caspase 3. |
|---|---|
| In Vivo | In vivo, inhibition of caspase-8 by Z-IETD-FMK reduces memory/activated CD4 and CD8 T cells, and increases susceptibility to T. cruzi infection. Z-IETD-FMK promotes neuronal survival and regeneration of injured retinal ganglion cells after CNS injuries. |
| Animal model | T. cruzi-infected mice |
| Formulation & Dosage | DMSO/PBS (15%); 0.4 mg/3 days |
| References | [1] Silva EM, et al. J Immunol. 2005, 174(10), 6314-6321. [2] Monnier PP, et al. J Neurosci. 2011, 31(29), 10494-10505. |
|
|
|
|
m.cnreagent.com
